Acquires and advances drug candidates through subsidiaries and partners, and commercializes medicines for patients with skin conditions and other diseases.
10-K for FY2025, filed Mar 31, 2026Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company focused on acquiring and advancing assets to enhance…View ↗
Following the exclusive license or other acquisition of the intellectual property underpinning a product or product candidate, Fortress…View ↗
Our subsidiary and partner companies that are pursuing development and/or commercialization of biopharmaceutical products and product…View ↗
Through our partner company Journey we market the following branded dermatology products approved by the FDA for sale in the United States:View ↗
Most revenue comes from product deliveries, paid for when customers receive them; Fortress also receives royalties and milestone payments through partner agreements.
10-K for FY2025, filed Mar 31, 2026The Company records and recognizes revenue in a manner that depicts the transfer of promised goods or services to customers in an amount…View ↗
Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company focused on acquiring and advancing assets to enhance…View ↗
Cyprium is eligible to receive up to $128 million in aggregate sales milestones from Sentynl, as well as royalties on net sales of ZYCUBO…View ↗
10-K for FY2025, filed Mar 31, 2026
FY2025 revenue by product or service ↗$63.3M
10-K for FY2025, filed Mar 31, 2026
$63.3M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Emrosi
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
24% |
Emrosi, FY2025
$14.7M Sources
|
Sold outright |
|
Qbrexza
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
41%
FY2022: 38%
|
Qbrexza, FY2025
$25M Sources
|
Sold outright |
|
Accutane
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
21%
FY2022: 26%
|
Accutane, FY2025
$12.9M Sources
|
Sold outright |
|
Foam franchise products (Amzeeq & Zilxi)
Sold outright
10-K for FY2025, filed Mar 31, 2026 |
9.6% |
Foam franchise products (Amzeeq & Zilxi), FY2025
$5.9M Sources
|
Sold outright |
|
Other / legacy product revenue
Sold outright
|
4.5% |
Other / legacy product revenue, FY2025
$2.7M Sources
|
Sold outright |
The company sells through wholesalers to contracted indirect customers and qualified government healthcare providers; specialty pharmacies also handle its products, and some commercial payers have rebate agreements.
10-K for FY2025, filed Mar 31, 2026Chargebacks and Government Chargebacks — The Company sells a portion of its products indirectly through wholesaler distributors to…View ↗
Specialty Pharmacy Discounts — The Company has in place contractual arrangements with specialty pharmacies and provides for contractually…View ↗
Managed Care Rebates — The Company is subject to rebates in connection with its agreements with certain contracted commercial payers. The…View ↗
Yes. It kept 11 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$65.8M.
10-Q for Q3 FY2026, filed Nov 13, 2026
−$5.8MView ↗
10-Q for Q3 FY2026, filed Nov 13, 2026
Open tableView ↗
8-K, filed Nov 13, 2026
Fortress Subsidiary Licenses FB-607 for IBS-D. In the third quarter of 2026, a majority-owned and controlled private subsidiary of Fortress…View ↗
Shrinking. Revenue fell 8% in 4 years, from $68.8M in FY2021 to $63.3M in FY2025, about 2% a year.
New dermatology medicine
The newer business section adds Emrosi, an oral rosacea medicine, to Journey's marketed dermatology portfolio; the earlier report's marketed-product list did not include it.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 31, 2026
Competes with Galderma Laboratories, Almirall, Leo Pharma, Mayne Pharma, Botanix Pharmaceuticals, and Ortho Dermatologics
10-K for FY2025, filed Mar 31, 2026Our major competitors in dermatology, including Galderma Laboratories, Almirall, Leo Pharma, Mayne Pharma, Botanix Pharmaceuticals, and…View ↗
Loading...